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ABSTRACT 
Objective: Since the 1970s, one of the smallest Indian States, Kerala, has been internationally applauded for its excellent performance in its health 
indicators. Even if mortality is low, the morbidity (those suffering from chronic/non-communicable diseases) levels in urban and rural is high in 
Kerala compared to other Indian states. Gradually, the public sector becomes incapable to convene the demands for health care and people have 
responded to this meagerness by increasing the use of an emerging private sector. To overcome this scenario, Kerala government established KMSCL 
for promoting access to medicines to the patients approaching the public hospitals in Kerala by making available selected essential medicines at free of cost. 
The present study was conducted to evaluate the availability, cost and affordability of anti-hypertensive medicines in Kerala.  
Methods: This prospective, observational study was conducted in Trivandrum district in Kerala, from June 2013 to November 2013. Three types of 
medication prices were taken into contemplation with the intension for calculation purposes, the highest and the lowest branded medication costs 
in private pharmacy and Karunya Community Pharmacy (KCP) prices. Affordability was calculated for the different level of skilled workers and 
through the wages fixed by the government of Kerala for these categories, who were consuming the medications at the time. A comparison was also 
done between various treatment guidelines of hypertension.  
Results: There was 15.5% to 230% price variation between the highest and lowest price of branded anti-hypertensive medicines respectively. For 
treating Stage 3 of hypertension; unskilled and highly skilled workers had to spend a minimum of 1.22 and 0.84 wage days respectively and a 
maximum of 5.23 and 4.34 wage days respectively in private pharmacies. All the medicines required for the treatments of hypertension were 
available in both private and KCP.  
Conclusion: The study revealed that there was an average availability at of antihypertensive medicines in public health facilities. The availability of 
all medicines at KCP in low price shows the good impact of KMSCL for promoting access of medicines to the poor. 
Keywords: Hypertension, Medicine Price, Karunya Community Pharmacy, Public sector. 
 
INTRODUCTION 
India has a flourishing drug industry and has played a major role to 
making generics at low prices worldwide [1]. Generate 8 per cent of 
the medicines available in the global market and ranks 3rd in terms 
of volume and ranks 13th in world production by value [2]. We are 
truly proud of this. But medicines situation within India is quite 
different they are overpriced and unaffordable, a glaring silent 
violation of human rights [1]. Inequitable access to medicines is a 
major drawback in the Indian health care system. Nearly sixty per 
cent (499-649 million) of the population in India does not have 
reliable access to essential medicines. [3][2] 
About 60-90 per cent of healthcare spending by poor people is on 
medicines. The main focus of the government’s drug policies has 
been on the manufacturing and marketing of drugs to various 
countries and the private sectors, and not much focused on 
improving accessibility of essential medicines for the people [2]. A 
total of 347 essential drugs were brought under price control in the 
Drug Price Control Order (DPCO) of 1979. Later on the drug 
companies have succeeded in reducing the basket of price controlled 
drugs to 142 drugs in 1987. By 1995, it eroded to 76 drugs and only 
74 out of about 550 commonly used drugs are under legal price 
control. So that for the remaining drugs there is no ceiling on drug 
prices and the companies are free to fix the maximum retail price 
(MRP) of their own choice, which could be 5 to 10 times or even 
more the actual production cost [4].  
The Department of Pharmaceuticals had notified the Drugs (Prices 
Control) Order 2013, under which prices of 348 medicines in the 
National List of Essential Medicines (NLEM) have been brought 
under price control, thus replacing an earlier order of 1995 that 
regulated prices of only 74 bulk drugs. 
The Government of Kerala constituted Kerala Medical Services 
Corporation (KMSCL) with the primary objective of making available 
quality medicines, surgical items and other hospital requisites to all 
the patients through the public health care networks and for that 
purpose procure the medicines at most economical rates. The 
Karunya Community Pharmacy (KCP) under the control of 
Community Pharmacy Services (CPS) division of KMSCL is a valiant 
intervention of Govt. of Kerala to reduce the Out-of-Pocket 
expenditure incurred by the common man, for the huge expenditure 
on medicines. The KCP scheme helps to provide medicines which are 
not available in government hospitals for free supply, at reduced/ 
subsidised prices to the patients in a hitherto unknown professional 
manner. 
The high cost of medications affects the most prevalent illness of Kerala, 
which is hypertension. Recent surveys in different categories of subjects 
in Kerala reveal that one out of three adults in Kerala is a hypertensive. 
Hypertension leads to heart attacks, stroke and kidney failure. It is a 
lifetime disease and needs careful and sensible management throughout 
life.[5] There was a high prevalence of hypertension in Kerala compared 
to other parts of India. Highest rate of prevalence was observed in 
Thiruvananthapuram city in Kerala (30.7%). Elderly sample population 
has a very high prevalence of hypertension (52%) in Kerala.[6]. 40.6% of 
adult males and 38.5% of adult females of our State are hypertensive 
compared to the national average of 30.7% and 31.9% respectively[7]. 
The primary goal of therapy of hypertension should be effective 
control of BP in order to stop, reverse or holdup the development of 
complications and thus reduce the overall risk of an individual 
without adversely affecting the quality of life. According to Indian 
Hypertension guidelines by The Association of Physicians of India 
(API) Younger individuals have high renin hypertension, therefore 
ACE inhibitors/ARBs or beta-blockers are favored; while older 
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individuals have low renin hypertension and hence diuretics or CCBs 
are preferred as first line agents[8]. 
In combination, one out of the two groups A [ACE inhibitor/ ARB] or 
B [beta-blocker] is combined with C [calcium channel blocker] or D 
[thiazide diuretic] (step 2) In refractory patients, when 3 agents are 
to be used, A+C+D is a good choice (step 3) The combined use of 
diuretics and beta-blockers is discouraged due to a high incidence of 
new-onset 9 diabetes. 
According to the Treatment protocol of hypertension by government 
of Kerala (Directorate of Health Services) medicines presented are 
Amlodipine 2.5mg to 5mg, Enalapril/ Lisnopril 2.5mg -10mg, 
Chlorthalidone 6.25- 25mg /Hydrochlorothiazide 12.5- 50mg, 
Losartan 25-50mg[9]. 
Objectives 
The objectives of the present study are to determine the availability 
of medicines for the treatment of hypertension in the government 
hospital and community pharmacies in Kerala. To calculate retail 
pharmacy medicine prices and assess their affordability and to 
calculate Karunya Community pharmacy medicine prices and 
assesses their affordability. 
MATERIALS AND METHODS 
A prospective, observational study was conducted in 
Thiruvananthapuram, capital city of Kerala, from June 2013 to 
November 2013. The methodology was designed from earlier 
studies of availability and affordability of medicines, after the critical 
evaluation by all study investigators. Survey sites was urban City 
Corporation Area of Thiruvananthapuram district in the state of 
Kerala, with population of 33,07,284(15,84,200 – males, 17,23,084 – 
females) and literacy rate of 92.66% (94.60% male and 90.89% 
female) according to the census report of 2011[10]. The selection of 
the sample population, consisting of both public hospitals and 
private pharmacies was based as per the WHO manual comprising of 
indicators for assessing national drug policies. The district was 
separated into three geographical area, Highlands, Midlands, and 
Lowlands. Chirayinkeezhu, and Thiruvananthapuram Taluks 
situated on the midland and lowland regions, while the Nedumangad 
Taluk situated in the midland and highland regions, and the 
Neyyattinkara Taluk extended over all the three regions. Thus the 
study site was divided into four taluks. Out of each unit, a sample of 
at least 20 pharmacy units is required (in each zone five retail 
pharmacy and five government hospitals included in the study). The 
private pharmacies were selected based on the following criteria: 
first- the proximity of the private pharmacy to a public health 
facility, second the willingness of the pharmacy owner to allow the 
survey. Initially ten pharmacies were identified in each zone, then 
screened to 5 pharmacies which are located in five km radius. Out of 
which five selected on the basis of stock maintenance, prominence, 
accessibility and sales turn over were considered while selecting the 
community pharmacies (private pharmacies). Availability: For one 
calendar month, i. e., 4th January – 4th February 2014, data was 
collected by studying the availability of anti-hypertensive 
medication stock at the study sites i. e. Government hospitals and 
community pharmacies. The medication stock was accounted for 
thrice during the study, on the 1st day, at the end of 2 weeks and at 
the end of 4 weeks. From the Hypertension treatment protocol by 
Gov. of Kerala (DHS) identified 6 medicines for the treatment. The 
medicines used for stage 1 hypertension and stage 2 hypertension 
were included in the survey they are, Amlodipine, Enalapril/ 
lisinopril, Combination of Amlodipine and Enlapril or Lisnopril, 
Combination of Amlodipine, Enlapril/ Lisnopril and Chlorthalidone / 
Hydrochlorothiazide, Combination of Amlodipine, Enlapril/ 
lisinopril, Chlorthalidone / Hydrochlorothiazide and Losartan. These 
medicines list were compared with NRHM Hypertension Guidelines 
and JNC 8 Hypertension Guidelines. 
Affordability and Cost of Medicines: The cost of the medicine was 
calculated based on the specific condition of the patient and the 
dosage of the medication proposed the Hypertension treatment 
protocol by the government of Kerala. The prices of medicines were 
sorted as highest price, lowest price and Karunya community 
pharmacy price. The highest and lowest prices of the brands were 
taken from CIMS (Oct 2013- Jan 2014). Karunya Pharmacy medicine 
price was obtained from karunya pharmacy situated in 
Thiruvananthapuram. The total prices of medications were 
calculated for ten days of treatment as hypertension was chronic 
disease and lifelong medications were required. The affordability of 
medicines in the private sector was evaluated by considering the cost of 
treatment of hypertension and the minimum wages earned per day by 
different categories of workers; as specified by the gazette notification of 
Labour Ministry, Government of Kerala, 2011 [11]. The number of days a 
daily wage earns would have to work to procure the cost of treatment of 
hypertension been accessed, lowest, highest and Karunya community 
pharmacy costs of medications was obtained in the survey. The 
percentage difference between the maximum and minimum cost of 
treatment of hypertension was calculated as 




Table 1 indicates the recommended drug of choice to treat hypertension, 
according to the condition of the patients. According to the Hypertension 
Treatment Protocol, three stages have been proposed and each stage 
requires different treatment. The minimum and maximum prices of the 
branded and their percentage difference and Karunya community 
pharmacy prices are summarized in table 1. 
The total minimum and maximum cost required for one month 
treatment of hypertension for stage one is Rs. 16.47 to Rs. 132, In 
KCP, were they sell both branded and generic and the minimum and 
maximum cost required for the same treatment is 17.1 to 103.5. In 
KCP even the branded medicines are available to patients for a low 
cost. In private medical shops the percentage of price difference 
between minimum and maximum ranges from 113 to 1040. All the 
medicines which required for the treatment for hypertension were 
available at KCP. 
Table 2 illustrates a comparison of the guidelines such as NRHM, JNC 
8, and Treatment Protocol for hypertension by Kerala government. 
In which, Beta Blockers which was mentioned in both NRHM 
guidelines and JNC 8, were not included in the treatment protocol of 
Hypertension by Kerala Gov., some of the medicines listed in those 
were not available in Kerala Essential Drug List, such as Lisnopril 
which cost around a minimum of 2.51 Rs and a maximum of 5.5 Rs 
in private sector, Chlorthalidone which cost around 1.28 Rs. 
Similarly, wage days were calculated for treatment using anti 
hypertensive drugs for each stage. Table 3 represents the 
affordability of antihypertensive agents for different categories of 
workers in the year 2011 in the state of Kerala. For one month of 
treatment with antihypertensive drugs for an initial stage; unskilled, 
semiskilled, skilled and highly skilled workers required minimum 
and maximum of 0.149 and 1.19, 0.144 and 1.15, 0.13 and 1.08, 0.12 
and 0.99 wage days respectively in private pharmacies. Similarly, 
wage days were calculated for treating step two hypertension which 
required 0.88 and 3.83, 0.85 and 3.70, 0.80 and 3.46, 0.73 and 3.17 
respectively. For Step three hypertension treatments required 0.78 
and 3.68, 0.75 and 3.56, 0.71 and 3.33, 0.65 and 3.05 wage days. For 
step four required 1.22 and 5.23, 1.17 and 5.05, 1.10 and 4.73, 0.84 
and 3.65wage days respectively. 
 
Fig. 1: Availability of selected antihypertensives medicines at 
public healthcare facility 
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Figure one, Contains the detail of availability of selected 
antihypertensive drugs by Gov. of Kerala (Treatment Protocol) at 
one CHC, three primary health care facility and one Taluk Hospital of 
four survey area. All the drugs listed were available in private 
pharmacies.  
Chloroquine and Lisnopril were not listed in EDL so those drugs 
were not available at Public health facilities. The availability of 
enalapril and amlodipine 2.5 mg was low as the doctors prescribing 
those medicines were not frequent now days. All the medicines 
surveyed were available at KCP. 
 [ 
Table 1: Recommended drug of choice and prices of antihypertensive medications in private retail pharmacy and Karunya Community 
Pharmacy Prices. 
S. No. Treatment of 
hypertension 
stages 
Medicines For 30 days of treatment 










1 Step 1 Amlodipine 2.5mg or 16.47 132 701 17.1 103.5 505.26 
  Enlapril 2.5 mg 26.4 67.8 156.81 24.6 54 119.51 
  Or       
  Amlodipine 5mg or 22.62 258 1040 21 201.6 860 
  Enalapril 10mg 83.25 178.08 113.90 111 135 21.62 
2 Step 2 Amlodipine 5mg + 
Enalapril 5mg 
48.12 368.52 665.83 60 296.1 393 
  Or       
  Amlodipine 5mg + 
Lisnopril 5mg 
97.92 423 331.98 154.5 282.9 83.10 
3 Step 3 Amlodipine 5mg + 
Enalapril 5mg + 
Chlorthalidone 25mg  
86.64 406.92 369.66 94.5 330.6 249 
  Or       
  Amlodipine 5mg + 
Enalapril 5mg + 
Hydrochlorothiazide 
25mg 
63 315.42 400.66 73.5 192 161 
  Or        
  Amlodipine 5mg + 
Lisnopril 5mg+ 
Chlorthalidone 25mg 
136.44 461.52 238.25 189 317.4 67.93 
  Or       




112.8 369.9 227.92 168 245.4 46.07 
4 Step 4 Amlodipine 5mg + 
Chlorthalidone 25mg+ 
Losartan 50mg 
134.64 578.07 329.34 112.2 425.1 278 
  Or       
  Amlodipine 5mg + 
Hydrochlorothiazide 
25mg+ Losartan 50mg 
111 486.45 338.24 91.2 286.5 214 
 
Table 2: Comparison of Hypertension treatment Guidelines and availability in Kerala EDL 
NRHM Guidelines JNC 8 guidelines Gov. of Kerala Treatment 
Protocol  
Kerala EDL 
ACE inhibitors ACE inhibitors ACE inhibitors ACE inhibitors 
Enalapril 5 mg Captopril 50mg Enalapril 2.5mg Enalapril 2.5mg 
Perindopril 4mg Enlapril 5mg Enalapril 5mg Enalapril 5mg 
Ramipril 5mg  Lisinopril 10mg Lisnopril 5mg Angiotensin receptor blockers 
Angiotensin receptor blockers Angiotensin receptor blockers Thiazide-type diuretics Losartan 25mg 
Losartan 50 mg  Eprosartan 400mg Chlorthalidone 25mg β-Blockers 
Valsartan 40 mg Candesartan 4mg Hydrochlorthiazide 25mg Atenolol 50mg 
β-Blockers losartan 50mg Angiotensin receptor blockers Metoprolol 25mg 
Atenolol 25 mg valsartan 40mg Losartan 50mg Metoprolol 50mg 
Proponolol 40mg Irbesartan 75mg Calcium channel blockers Calcium channel blockers 
Metoprolol 50 mg β-Blockers Amlodipine 5mg Amlodipine 2.5 mg 
Calcium channel blockers Atenolol 25mg Amlodipine 2.5mg Amlodipine 5mg 
Amlodipine 2.5 mg Metaprolol 50mg  Nifedipine 5mg 
Diltiazem extended release 120 mg Calcium channel blockers  Nifedipine 10mg 
Nifidipine 30MG (long acting) Amlodipine 2.5 mg   Diltiazem 30mg 
Thiazide-type diuretics Diltiazem extended release 120 mg Diuretics 
Hydrochlorothiazide 12.5mg Nitrendipine 10mg  Frusemide Inj 10mg 
Indapamide 2.5mg Thiazide-type diuretics  Frusemide 40mg 
Central α 2 agonists and other  
centrally acting drug 
Bendroflumethiazide 5  Hydrochlorthiazide 25mg 
Clonidine 0.15MG Chlorthalidone 12.5  Spironolactone 25mg 
Methyl dopa 250 MG Hydrochlorthiazide 12.5   
Alpha blockers Indapamide 1.25   
Prazosin 2.5 MG    
Lekshmi et al. 




Table 3: Affordability of hypertension treatment for ten days Treatment (in Year 2011) 
S. No. Treatment of 
hypertension stages 
Medicines Unskilled Semiskilled Skilled Highly Skilled 
1 Step 1 Amlodipine 2.5mg or 0.149/1.19 0.144/1.15 0.13/1.08 0.12/0.99 
  Enlapril 2.5 mg 0.23/0.61 0.23/0.59 0.21/0.55 0.06/0.17 
  Or     
  Amlodipine 5mg or 0.20/2.33 0.19/2.25 0.18/2.11 0.16/1.93 
  Enalapril 10mg 0.75/1.61 0.72/1.55 0.68/1.45 0.62/1.33 
2 Step 2 Amlodipine 5mg + Enalapril 5mg 0.43/3.33 0.42/3.22 0.39/3.02 0.36/2.76 
  Or     
  Amlodipine 5mg + Lisnopril 5mg 0.88/3.83 0.85/3.70 0.80/3.46 0.73/3.17 
3 Step 3 Amlodipine 5mg + Enalapril 5mg + 
Chlorthalidone 25mg  
0.78/3.68 0.75/3.56 0.71/3.33 0.65/3.05 
  Or     
  Amlodipine 5mg + Enalapril 5mg + 
Hydrochlorothiazide 25mg 
0.57/2.85 0.55/2.75 0.51/2.58 0.47/2.36 
  Or      
  Amlodipine 5mg + Lisnopril 5mg+ 
Chlorthalidone 25mg 
1.23/4.18 1.19/4.03 1.11/3.78 1.02/3.46 
  Or     
  Amlodipine 5mg + Lisnopril 5mg+ 
Hydrochlorothiazide 25mg 
1.02/3.35 0.98/3.23 0.92/3.03 0.84/2.77 
4 Step 4 Amlodipine 5mg + Chlorthalidone 25mg+ 
Losartan 50mg 
1.22/5.23 1.17/5.05 1.10/4.73 0.84/4.34 
  Or     
  Amlodipine 5mg + Hydrochlorothiazide 25mg+ 
Losartan 50mg 
1.00/4.40 0.97/4.25 0.90/3.98 0.83/3.65 
 
DISCUSSION 
The state of Kerala, with just over 3 % of the national population has 
attained the status of number one position in per capita medicine 
consumption. It is estimated that 9- 11 % of Indian domestic 
medicine market share is consumed in the state. Access to essential 
medicine is over 78 % in the state against the national average of 
33% and the global average of 66 %. [12] The State has reported the 
highest proportion of hospitalized persons both in rural and urban 
areas. Share of public providers in non-hospitalized medical 
treatment of ailments in Kerala is higher than that of all India 
percentages (Kerala Rural- 37%; Kerala urban- 22%; India rural- 
2%; India urban- 19%)[5]. Also, there is a decreasing trend in the 
hospitalized treatment from public sources in Kerala. The cost of 
treatment is the lowest in Kerala even now, both in rural and urban 
areas, compared to other states though it has increased significantly 
over the years. According to NSSO 60th round conducted in2004, the 
average medical and other related non-medical expenditure per 
treated person during 15 days preceding the survey was Rs. 182 in 
rural areas and Rs. 193 in urban areas of Kerala while the national 
averages were Rs. 257 in rural areas and Rs. 306 in urban areas. The 
position of Kerala is the reverse, where only 37 percent secured 
treatment from public hospitals, while 63 percent secured treatment 
from private and corporate.[13] In India, more than 68 % (Census 
2011) populations live in rural area and they work on farms or 
perform other menial jobs which pay on a day to day basis. The poor 
people mostly depend on the government hospitals for healthcare. 
Our study also point out that the price of anti hypertensive 
medicines in the private sector is very high compared to the Govt. 
Owned Community Pharmacy. Even though, public health facilities 
providing free or subsidized care, 81% of outpatient and 45% of 
inpatient care in India were assessing private healthcare. This may 
be due to the unused / under used potentials of many institutions 
such as a) Lack of periodic or annual maintenance of buildings 
resulting to dilapidated conditions. b) Non- availability of building / 
lack of proper electrification/ lack of water and sanitation facilities. 
c) Lack of manpower: Often building and equipment was 
constructed and established but the lack of man power results in 
idling of a facility. d) Lack of sufficient equipment and 
furniture.(rusty and unrepaired cots, spoilt mattress and torn dirty 
bed sheets or their absence is a common sight in many of the 
government healthcare institutions. e) Majority of them may not 
even have basic clinical investigation facilities and may even lack life 
supporting facilities like round the clock availability of oxygen etc. f) 
shortage of medicine due to the irregular supply of medicines and 
other materials, so patients seeking medical care from the 
government hospitals are forced to buy them from outside, curt 
attitudes of doctors and other staff members, corruption, deficiency 
of hygiene. 
Consequently affordability of medicines was a major issue. For one 
month of hypertension treatment an unskilled worker has to spend 
0.149-5.23 days wage require from minimum price brand to 
maximum price in private pharmacies similarly for other class of 
workers. (Table 2) 
Large variation in costs of medicines was viewed. In India, the 
pricing policy for medicines was disoriented which was a major 
reason for the price variation. The prices of all medicines were not 
under price control and have been left to the market forces. The 
maximum allowable post manufacturing expense (MAPE) permitted 
for medicines under price control is 100 percent and ceiling prices 
have been fixed for these For the other medicines, there is no 
restriction on the MAPE, resulting in large and variable prices. The 
variation in prices of the same medicine but sold under different 
brands is large and may range from 25-3400 percent [14]. 
The results of this study emphasize the need to improve medication 
availability and increase affordability of medicine for hypertension, 
particularly in the public sector. Although many medicines for 
hypertension as well as for other diseases were theoretically 
provided for free cost in the public sector, but all the medicines were 
not available in the public institutions, leading to patients 
purchasing them from private community pharmacies at higher 
costs [15]. Branded medications are more costly than their generic 
equivalents, but in India many branded medications are not 
available, as a result of which their generic counterparts are overtly 
pricey. In our study the price difference comparison was minimum 
for enalapril 113% and maximum for Amlodipine 1040 %. Generic 
medications are cheaper compared to brand medications but they 
are not much available in the government facilities. As a result, the 
same cheap generic medications are sold in the market at a high 
price and which make poor patient to spend out of pocket.  
The Karunya Community Pharmacy under the control of Community 
Pharmacy Services (CPS) division of KMSCL was a courageous 
intervention of Govt. of Kerala to reduce the Out-of-Pocket 
expenditure of the society, mostly because of the great expenditure 
on medicines. The first outlet at Medical college, Trivandrum opened 
Lekshmi et al. 




on 12thJanuary 2012. Main features of Karunya Community 
Pharmacy are: 20-90% discount from MRP for all medicines, 
Operational 24 X 7 Advanced inventory supply management system, 
State of art scientific warehousing (Karunya Medicine Depots) and 
Patient counseling. Specialty drugs are mostly given in purchase rate 
itself without taking any margin. 
 
Table 4: Below shows the price difference which Karunya community pharmacy offers to the public. 
S. No. Medicine name MRP KCP rate(Rs) %difference 
1 Zoledronic Acid(ALZIC Inj) 2,450.00 176.75 92.78 
2 Dobutamine(DOBUSTAT Inj 5 ml) 259.00 28.75 88.89 
3 Human Albumin(ALBUREL) 5000.00 2100.00 58 
4 Peginterferon alpha 2a (PEGASYS PFS 135 MCG) 12415.00 6842.00 44.88 
5 Liposomal Amphotericin (AMPHOCEL 50 MG vial) 7990.00 2950.00 63.07 
 
 
Fig. 2: Sales analysis during the period from 12.01.12 to 
03.11.12 
 
This drastic increase in sales of KCP shows that the poor patients are 
getting the branded medicines in much a reduced cost than the 
private pharmacy price. The number of people resorting to the 
public healthcare system increased during last 15 years. A study by 
Kerala Sasthra Sahytya Parishath(KSSP) comparing the scenario in 
1996 to that of 2004 showed that 28% of the population was 
dependent on the government sector in 1996 and it increased to 
32% in 2004. Kerala is the first state to implement the union 
government’s initiative to supply free generic medicine to patients 
through government hospitals from November 1st; 2012. A 
significant increase in the number of outpatients has been reported 
from the General Hospitals in Thiruvananthapuram, Ernakulam and 
Kozhikode following the launch of the free generic medicines 
scheme. Officials of the Kerala medical services corporation 
(KMSCL) declared that many patients from private hospitals are 
returning to government hospitals for free generic medicines and 
they said that there is a 50 to 100 percentage increase in the number 
of outpatients at these hospitals [16]. In order to make the 
availability of quality essential medicines in the public health care 
facilities of the state and to ensure their rational and prudent use, 
the following problems deserve special attention. 
Periodic updating and adherence to Essential Medicines List 
(EML) of the state 
The list of items in the EML has to be updated at regular intervals 
with the support of an effective addition/ deletion policy norms. It 
has to be made known to all those involved in the prescription 
writing and handling, indenting and dispensing of medicines. The 
KMSCL has to take the TNMSC model in popularising the EML hand 
books in an easy to refer format (pocket book for over coat) 
throughout the state health care facilities.  
Updating the Hospital Formulary system 
The Hospital Formulary system working in the state has to be 
strengthened, particularly in the specialty and tertiary care hospitals 
with the support of some mechanism ensuring continuous and 
persistent efforts in that regard till the objective is achieved.  
Accreditation of Pharmacy services in Hospitals and 
Communities 
There shall be a set up for accreditation of hospital and community 
pharmacies in the state with the objective of promoting good 
dispensing practices and good storage practices. It will also help to 
ensure the presence of the sufficient number of qualified 
pharmacists with identifiable uniform/ dress code in the pharmacies 
as initiated by the Kerala State Pharmacy Council. Accreditation will 
help to make pharmacy services more professional, ethical and 
scientific.  
Publication of standard treatment guidelines 
The absence of STG can lead to many difficulties in implementing a 
state policy on medicines. It is difficult to make available the 
required / needy medicines in the health care facilities without 
interruption without EDL and STGs. Lack of STG leads to duplication 
and multiplication of certain medicines in the KMSCL warehouses 
and the hospital pharmacies causing much difficulties and hardships 
to the inventory management. It also promotes different 
prescription pattern even for mild conditions. Publication of 
STG/STP is essential to promote rational drug use.  
Effective quality assurance process and timely testing facilities 
for medicines 
Being a consumer state without much pharmaceutical 
manufacturing units, the state has to take extra care in ensuring 
quality control and quality assurance aspects of medicines marketed 
and/ used in the state. Unethical marketing strategies adopted by 
certain corners and the delay in withdrawing drugs found ‘not of 
standard quality’ (NSQ) are examples of serious issues faced by the 
state. The quality control mechanism is in doldrums and about less 
than one% of the batches of medicines used in the state are tested in 
the drug testing laboratory of the drugs control department. The 
proposal for establishing four regional laboratories of the 
department is not moving in the expected speed/ manner. 
Computerized medicine registry for the state. 
The state is facing many threats in the case of medicines, their 
storage, distribution and usage both in public and private set ups. 
The drug safety has to be ensured with respect to their quality, 
authenticity, availability and affordability. Unapproved combination 
drugs, formulations and dosage forms; drugs with similar/ identical 
or same names, marketing of defective and manipulated 
pharmaceutical products, clandestine marketing network, clinical 
trials etc. are issues to be attended seriously. Currently the state is 
not having any set-up to have a data base on medicines used/ 
marketed in the state. Drugs with same and similar trade/brand 
names are available in the hospitals and community pharmacies 
with entirely different active ingredients. Some agencies supply 
medicines to the state and vanish from the scene. It is difficult to 
trace them out as they don’t have any office or premises anywhere. 
The drugs control department is helpless in this regard. In order to 
solve such issues and establish a system in the state, a computerized 
medicine registry has to be established.  
CONCLUSION 
Access to quality essential medicines at the government health 
facilities and at affordable prices at private pharmacies and hospitals 
is essential. The availability of antihypertensive medications is 
average in public sector, when compared with KCP and private 
pharmacies were all the antihypertensive medicines available. The 
high cost of the medicines in India makes treatment less affordable 
Lekshmi et al. 




for the poor sections of the population. The KCP prices are not the 
lowest as per the common beliefs, but they are significantly lower 
than the highest priced branded medication available in the market. 
The Government should consider in expanding the KCP services to 
other districts at the earliest, which will be benefit for the society. 
Even though the rule is there, make sure that doctors should 
prescribe generic medications and government should generate 
awareness among the people about the availability and quality of 
generic medications. Modifications and monitoring of 
pharmaceutical policy at the national and state level are necessary to 
improve affordability and hence access to medicines for the people. 
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